Investment
Neion Bio listed as new Digitalis Ventures portfolio company in Human Health portfolio - harnessing nature's molecular factories for affordable medicine.
Neion Bio
Added recently
Essay
Essay by Geoffrey W. Smith examining recursive self-improvement in AI as a question of aim rather than speed, discussing the economics of AI R&D automation and governance implications.
Digitalis Ventures
Digitalis VenturesDigitalis Ventures
AUG 26, 2026
Essay
Digitalis Ventures founder Geoffrey W. Smith publishes essay on recursive self-improvement, AI governance, and the direction of technical change in the Digitalis Notebook.
Geoffrey W. Smith - Recursive, Toward What?
AUG 26, 2026
Essay
Essay by Geoffrey W. Smith on directed technical change in biomedicine, arguing the equity gap in innovation is a direction problem rather than a market failure.
Digitalis Ventures
Digitalis VenturesDigitalis Ventures
JUL 23, 2026
Essay
Digitalis Ventures founder Geoffrey W. Smith publishes essay on directed technical change, market-size effects in biomedical innovation, and the equity gap in drug development.
Geoffrey W. Smith - Faster, Toward What?
JUL 23, 2026
Essay
Essay on AI agents and biomedical coordination costs, arguing agents compress the transactional layer but leave the governance layer of coordination untouched.
Digitalis Ventures
Digitalis VenturesDigitalis Ventures
JUN 30, 2026
Essay
Digitalis Ventures Technical Partner Dr. Cindy Cole publishes a Note on Animal Health on cannabis and animal health.
Cindy Cole - The Complex Conundrum of Cannabis
JUN 24, 2026